On Thursday, HD Supply Holdings Inc (NASDAQ:HDS)’s shares declined -0.45% to $35.10.
Many investors like to look for value in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for value investors in the near term.
This method discovered several great candidates for value-oriented investors, but recently let’s focus on HD Supply Holdings, Inc. (HDS) as this stock is looking especially impressive right now. And while there are numerous reasons why this is the case, we have highlighted three of the most vital reasons for HDS’s status as a solid value stock below:
Price to Forward Sales for HD Supply Holdings
One of the most underrated ratios for value investors is the price/forward sales metric. This ratio shows investors how much they are paying for each dollar of revenues generated. In other words, a lower number is better here while a price to sales ratio of 1 means that you are paying one dollar for each dollar in sales.
Forward PE for HD Supply Holdings
Easily one of the most popular readings for value investors, the forward PE ratio shows us the current price of a stock divided by the full year earnings. Generally speaking, value investors like to see this ratio below 20, though it can vary by industry.
HD Supply Holdings, Inc. operates as an industrial distributor in North America. The company’s Facilities Maintenance segment offers electrical and lighting items, plumbing, appliances, janitorial supplies, hardware, kitchen and bath cabinets, window coverings, textiles and guest amenities, healthcare maintenance, and water and wastewater treatment products, in addition to heating, ventilating, and air conditioning products. Its Waterworks segment provides pipes, fittings, valves, hydrants, and meters for use in the construction, maintenance, and repair of water and waste-water systems, in addition to fire-protection systems; and smart meters, fusible piping solutions, and engineered treatment plant products and services.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s shares dropped -4.63% to $8.04.
BioDelivery Sciences International, Inc. (BDSI) together with its merged auxiliaries, Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius”), and Arius Two, Inc., a Delaware corporation (“Arius Two”, and together with Arius, the “Auxiliaries”, and the Auxiliaries together with the Company, collectively, the “Borrowers”), reached a $30 million secured loan facility (the “Loan Transaction” and such loan, the “Loan”) with MidCap Financial Trust, as agent and lender (“MidCap”), following the terms and conditions of that certain Amended and Restated Credit and Security Agreement, dated as of May 29, 2015 (the “Credit Agreement”), among the Borrowers and MidCap. The Credit Agreement is a restatement, amendment and modification of a prior Credit and Security Agreement, dated as of July 5, 2013 (the “Prior Agreement”) among the Borrowers, MidCap Financial SBIC, LLP, a predecessor to MidCap, and certain lenders thereto. The Credit Agreement restructures, renews, extends and modifies the obligations under the Prior Agreement and the other financing documents executed in connection with the Prior Agreement (the “Prior Loan”). The amount of principle under the Prior Loan, which was comprised of as part of the Loan, was about $9.3 million. The Company received net Loan proceeds in the aggregate amount of about $20.1 million and will use the Loan proceeds for general corporate purposes or other activities of Borrower and its Auxiliaries permitted under the Credit Agreement.
The Loan has a term of 42 months, with interest only payments for the first 12 months. The interest rate is 8.45% plus a LIBOR floor of 0.5%, with straight line amortization, commencing on June 1, 2016, in an amount equal to $1 million per month. Upon execution of the Credit Agreement, the Company paid to MidCap a closing fee from the prior loan of about $445,000. Upon repayment in full of the Loan, the Company is obligated to make a final payment fee equal to 2.75% of the aggregate Loan amount. In addition, the Company may prepay all or any portion of the Loan at any time subject to a prepayment premium of: (i) 5% of the Loan amount prepaid in the first year following the execution of the Credit Agreement and (ii) 3% of the Loan amount prepaid in each year thereafter.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain administration and addiction.
At the end of Thursday’s trade, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)‘s shares dipped -0.96% to $128.35.
Vertex Pharmaceuticals Incorporated (VRTX) declared that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018.
Dr. Bhatia is a physician and engineer and has been a professor at the Massachusetts Institute of Technology (MIT) since 2005. She presently serves as the John J. and Dorothy Wilson Professor of Health Sciences at the MIT Institute for Medical Engineering and Science and Electrical Engineering and Computer Science (EECS). She also presently serves as a Biomedical Engineer in the Department of Medicine for Brigham and Women’s Hospital, an investigator for the Howard Hughes Medical Institute, a member of the Koch Institute for Integrative Cancer Research at MIT and a member of the Broad Institute. She recently received the Heinz Award for Technology, the Economy, and Employment from the Heinz Family Foundation and the Lemelson-MIT Prize for her dedication to STEM education and to improving human health through technological innovations. From 1998 to 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego. Dr. Bhatia holds a B.S. in Biomedical Engineering from Brown University, an M.S. in Mechanical Engineering and Ph.D. in Biomedical Engineering from MIT, and an M.D. from Harvard Medical School.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
Liberty Interactive Corp (NASDAQ:QVCA), ended its Thursday’s trading session with -0.17% loss, and closed at $28.62.
Liberty Interactive Corporation (QVCA)) declared that it has reached an agreement with Liberty Broadband Corporation (NASDAQ: LBRDA, LBRDK) (“Liberty Broadband”) whereby Liberty Interactive will invest $2.4 billion in Liberty Broadband in connection with (and contingent upon) the closing of declared projected merger of Charter Communications, Inc. (“Charter”) and Time Warner Cable Inc. (“TWC”). The proceeds of this investment will be used by Liberty Broadband to fund, in part, its agreement to acquire $4.3 billion of Charter stock. Liberty Broadband’s acquisition will be made in support of (and contingent upon) the closing of the Charter-TWC merger. In connection with these transactions, it is predictable that Charter will undergo a corporate reorganization, resulting in a current partner of Charter becoming the publicly traded parent company (“New Charter”). Liberty Interactive’s investment in Liberty Broadband will be funded using cash on hand and will be attributed to the Liberty Ventures Group.
Liberty Interactive Corporation, through its auxiliaries, engages in the video and on-line commerce industries in North America, Europe, and Asia. It markets and sells various consumer products primarily through live televised shopping programs, Websites, and mobile applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
